{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-097094","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2026-08-14T20:06:03+00:00","discovered_at":"2026-08-14T20:12:00.474959+00:00","generated_at":"2026-08-14T20:12:14.910216+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Quoin Q2 net loss $5.4M; FDA clears first-ever IND for Peeling Skin Syndrome","bullets":["Q2 2026 net loss $5.4M vs $3.7M in Q2 2025; six-month loss $10.4M vs $7.5M.","Cash, equivalents, and marketable securities $10.8M as of June 30, 2026; funds operations into 2027.","FDA conditionally approved QYLEKI as brand name for QRX003 (Netherton Syndrome) on June 23, 2026.","FDA cleared IND for QRX003 in Peeling Skin Syndrome on July 9, 2026; Phase 2/3 study to start 2H 2026.","USPTO issued Notice of Allowance for patent covering combination treatment for Netherton Syndrome on June 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-097094","json":"https://secwatch.observer/filing/0001104659-26-097094.json","markdown":"https://secwatch.observer/filing/0001104659-26-097094.md","text":"https://secwatch.observer/filing/0001104659-26-097094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926097094/0001104659-26-097094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926097094/tm2623115d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:12:14.910216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}